Mikkael A. Sekeres - Böcker

Written by the leading physicians in their respective fields - psychiatry and oncology - "Facing Cancer" is the only reference that combines top-tier medical information and compassionate counsel on cancer, its causes, and treatments with a caring approach to the emotional aspects of living with this diagnosis. This book gives you solid, trustworthy information in distinctive chapters that answer the most pertinent questions about cancer. It features integrative and complementary therapies, including faith and prayer, and the best medical advice on nutritional and other health-building lifestyle changes.

The only comprehensive guide to the clinical management of hematologic and lymphatic cancers4 STAR DOODY'S REVIEW!"This will be an ideal and a must-have book for anyone involved in the daily care of patients with hematologic malignancies. It would be particularly useful for physicians-in-training trying to make sense of the ever more complicated treatment plans for these patients....This is a unique book that provides easily accessible information that would be useful to almost any practicing oncologist or hematologist."--Doody's Review ServiceFilling an unmet need in the clinical literature, this commanding, just-in-time reference sheds light on the full spectrum of cancers in the blood, bone marrow, and lymphatic system (leukemia, lymphoma, myeloma). Clinical Malignant Hematology is edited by staff members from the renowned Taussig Cancer Center at the Cleveland Clinic, which has pioneered some of the most important clinical discoveries and treatment trends in recent years.Look inside and you'll see a consistent, unified patient management strategy in each chapter, as well as a streamlined three-section format that expertly examines ontogeny and physiology of blood cells, myeloid neoplasia, and lymphoid neoplasia. You'll also find never-before-published perspectives and precise recommendations for dosing and other critical areas that reflect the latest scholarship of this increasingly vital field.FeaturesFull coverage of all treatment modalities --chemotherapy, monoclonal antibodies, and hematopoietic stem cell transplantation Strong background chapters that offer guidance on how to address treatment complications and other supportive care issues A detailed, regimen-based orientation in each chapterAbundance of clinical pictures and photomicrographs displaying examples of peripheral blood smears and bone marrow aspiratesUniform headings and tables in each chapter, which convey specific recommendations on the work-up, staging, diagnosis, differential diagnosis, and treatment of hematologic malignancies Nearly 200 illustrations

How the FDA was shaped by public health crises and patient advocacy, told against a background of the contentious hearings on the breast cancer drug Avastin.Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimer’s drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate US authority on a drug’s safety and efficacy? In Drugs and the FDA, Mikkael Sekeres—a leading oncologist and former chair of the FDA’s cancer drug advisory committee—tells the story of how the FDA became the most trusted regulatory agency in the world. It took a series of tragedies and health crises, as well as patient advocacy, for the government to take responsibility for ensuring the efficacy and safety of drugs and medical devices. Before the FDA existed, drug makers could hawk any potion, claim treatment of any ailment, and make any promise on a label. But then, throughout the twentieth century, the government was forced to take action when children were poisoned by contaminated diphtheria and smallpox vaccines, an early antibiotic contained antifreeze, a drug prescribed for morning sickness in pregnancy caused babies to be born disfigured, and access to AIDS drugs was limited to a few clinical trials while thousands died. Sekeres describes all these events against the backdrop of the contentious 2011 hearings on the breast cancer drug Avastin, in which he participated as a panel member. The Avastin hearings, he says, put to the test a century of the FDA’s evolution, demonstrating how its system of checks and balances works—or doesn’t work.